<unk>  is approved in the United States for the treatment of prostate cancer in men and in Japan for the treatment of uterine fibroids (uterine leiomyoma) in women. It is used at a dosage of 120 mg once daily by mouth in the treatment of prostate cancer (after a single 360 mg loading dose on the first day of therapy) and at a dosage of 40 mg once daily in the treatment of uterine fibroids. Available forms<unk>  is available in the form of 40 and 120 mg oral tablets.
Relugolix
Elagolix
Lifitegrast
Deflazacort
Maralixibat chloride
Sufugolix
Seratrodast
Naloxegol